A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

NCT00282308 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Rituximab
DRUG: Methotrexate
DRUG: Methylprednisone
BIOLOGICAL: C. albicans
BIOLOGICAL: Tetanus toxoid adsorbed booster vaccine
BIOLOGICAL: 23-valent pneumococcal polysaccharide vaccine
BIOLOGICAL: Keyhole limpet hemocyanin

Sponsor

Genentech, Inc.